What is Leerink Partnrs’ Estimate for ARCT Q1 Earnings?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Arcturus Therapeutics in a report released on Wednesday, April 16th. Leerink Partnrs analyst L. Nsongo anticipates that the biotechnology company will earn ($1.24) per share for the quarter. The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.22) per share. Leerink Partnrs also issued estimates for Arcturus Therapeutics’ Q2 2025 earnings at ($1.74) EPS, Q3 2025 earnings at ($1.74) EPS, Q4 2025 earnings at ($1.71) EPS and FY2025 earnings at ($6.42) EPS.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.78). The firm had revenue of $22.77 million during the quarter, compared to the consensus estimate of $44.64 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%.

A number of other research analysts have also weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. Canaccord Genuity Group lowered their price objective on Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, March 10th. Wells Fargo & Company cut their target price on Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. Finally, BTIG Research set a $48.00 target price on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 10th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $59.20.

Arcturus Therapeutics Stock Up 2.2 %

Shares of ARCT opened at $10.53 on Friday. The business’s fifty day moving average is $13.26 and its 200 day moving average is $16.50. Arcturus Therapeutics has a 12-month low of $8.04 and a 12-month high of $45.00. The stock has a market cap of $285.57 million, a P/E ratio of -4.74 and a beta of 3.41.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Byrne Asset Management LLC raised its stake in shares of Arcturus Therapeutics by 89.8% during the 1st quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 1,365 shares during the period. Hennion & Walsh Asset Management Inc. raised its position in Arcturus Therapeutics by 21.0% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 99,254 shares of the biotechnology company’s stock worth $1,051,000 after acquiring an additional 17,197 shares during the period. Green Alpha Advisors LLC purchased a new position in Arcturus Therapeutics in the first quarter valued at about $288,000. GAMMA Investing LLC grew its position in shares of Arcturus Therapeutics by 3,482.9% during the 1st quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company’s stock valued at $550,000 after acquiring an additional 5,085 shares during the period. Finally, Woodline Partners LP grew its position in shares of Arcturus Therapeutics by 3.5% during the 4th quarter. Woodline Partners LP now owns 806,912 shares of the biotechnology company’s stock valued at $13,693,000 after acquiring an additional 26,956 shares during the period. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.